Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL

Ibrutinib (ibr), a first-in-class Bruton tyrosine kinase (BTK) inhibitor, has demonstrated high response rates in both relapsed/refractory and treatment naïve chronic lymphocytic leukemia (CLL). However, about 25% of patients discontinue ibrutinib therapy at a median follow-up of 20 months and many...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Shruti, Galanina, Natalie, Guo, Ailin, Lee, Jimmy, Kadri, Sabah, Van Slambrouck, Charles, Long, Bradley, Wang, Weige, Ming, Mei, Furtado, Larissa V., Segal, Jeremy P., Stock, Wendy, Venkataraman, Girish, Tang, Wei-Jen, Lu, Pin, Wang, Yue Lynn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356593/
https://www.ncbi.nlm.nih.gov/pubmed/27626698
http://dx.doi.org/10.18632/oncotarget.11932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356593/
https://www.ncbi.nlm.nih.gov/pubmed/27626698
http://dx.doi.org/10.18632/oncotarget.11932

Ejemplares similares